
Formats: [HTML](/news/2015/04/17/mylan-a-manufacturer-of-generic-drugs-announced-that-its-board-has-no-interest-in-much-discussed-prospect-of-purchase-by-teva-pharmaceutic.html)  [JSON](/news/2015/04/17/mylan-a-manufacturer-of-generic-drugs-announced-that-its-board-has-no-interest-in-much-discussed-prospect-of-purchase-by-teva-pharmaceutic.json)  [XML](/news/2015/04/17/mylan-a-manufacturer-of-generic-drugs-announced-that-its-board-has-no-interest-in-much-discussed-prospect-of-purchase-by-teva-pharmaceutic.xml)  

### [2015-04-17](/news/2015/04/17/index.md)

##### Mylan
# Mylan, a manufacturer of generic drugs, announced that its board has no interest in much-discussed prospect of purchase by Teva Pharmaceuticals, one of the 15 largest pharmaceutical concerns in the world. 

Generic drugmaker Mylan NV moved quickly on Friday to pour cold water on published reportsthat Teva Pharmaceuticals Industries is considering abid to acquire it.


### Sources:

1. [Reuters](https://www.reuters.com/article/2015/04/17/mylan-ma-teva-pharm-ind-idUSL4N0XE51620150417)
1. [Cover Image](https://s4.reutersmedia.net/resources_v2/images/rcom-default.png)

### Related:

1. [Mylan pays US$465 million to settle its underpayment to U.S. government healthcare programs by misclassifying its epinephrine autoinjector emergency allergy treatment. ](/news/2016/10/7/mylan-pays-us-465-million-to-settle-its-underpayment-to-u-s-government-healthcare-programs-by-misclassifying-its-epinephrine-autoinjector-e.md) _Context: Mylan_
2. [Israeli generics giant Teva Pharmaceutical offers $4 billion to acquire US rival Mylan. ](/news/2015/04/21/israeli-generics-giant-teva-pharmaceutical-offers-4-billion-to-acquire-us-rival-mylan.md) _Context: Mylan_
3. [A U.S. federal district court in Delaware rules in favor of Cephalon, a phamaceutical company, in a patent infringement lawsuit it had brought against a manufacturer of generic drugs. ](/news/2011/03/24/a-u-s-federal-district-court-in-delaware-rules-in-favor-of-cephalon-a-phamaceutical-company-in-a-patent-infringement-lawsuit-it-had-broug.md) _Context: generic drugs_
4. [The U.S. Court of Appeals, Federal Circuit, upheld an injunction issued by a federal district court in Indiana in 2009, enjoining Teva Pharmaceuticals from the marketing of its drug for the treatment of osteoporosis. The district court found, and the appellate court agrees, that Teva's drug is in violation of a valid patent held by Eli Lilly & Co.. ](/news/2010/09/1/the-u-s-court-of-appeals-federal-circuit-upheld-an-injunction-issued-by-a-federal-district-court-in-indiana-in-2009-enjoining-teva-pharm.md) _Context: Teva Pharmaceuticals_
